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Background. The aim of the study was to investigate the changes in plasma lipids and lipoproteins and the cardiovascular events
after selective LDL apheresis. Methods and Results. Two pediatric patients with familial hypercholesterolemia aged 11 and 13 years
and 19 dyslipidemic adults aged 41±14 years underwent direct adsorption of lipoproteins (DALI) sessions. The mean follow-
up period was 47±23 months. The total cholesterol (TC) values before and after treatment were 8.2±2.2 and 3.1±1.6mmol/l
(318±86and122±62mg/dL),respectively.TheintervalmeanofTCwas6.9±1.9mmol/l(268±75mg/dL).TheLDLcholesterol
concentrations before and after treatment were 6.6±2.1 and 1.7±1.1mmol/l, (256±82mg/dL and 65±41mg/dL), respectively.
The percentage of acute LDL cholesterol reduction was 75±11%. Cardiovascular events were observed in seven patients. The
average annual event rate was 5.51%. Conclusion. LDL apheresis is a very important therapeutic tool in managing patients at high
risk for premature CAD or with aggressive CAD, despite adequate medical treatment.
1.Introduction
The relationship between serum cholesterol and the risk of
cardiovascular disease has been ﬁrmly established. For more
than 2 decades, multiple clinical trials have documented the
cardiovascular beneﬁt of lowering low-density lipoprotein
(LDL)cholesterol.Familialhypercholesterolemia(FH)isone
of the most common genetic disorders, characterized by in-
creased levels of LDL cholesterol, tendons’ xanthomas, and
premature atherosclerosis [1]. The frequency of heterozy-
gous (hFH) in most populations is 1 in 500 births with ex-
ceptions in Christian Lebanese, where is 1 in 170 births,
Afrikaner1in70–100births,andFrenchCanadianancestries
1 in 200 births [1, 2]. The homozygous (HFH) is very rare (1
in 1000000 births) with symptoms presenting during child-
hood and early death due to coronary artery disease (CAD).
Approximately 22000 individuals in Greece are assumed to
be hFH, with the majority of them being undiagnosed. FH
can be caused by mutations in LDL receptor gene (LDLR),
the apolipoprotein B-100 gene (APOB), and the protein
convertase subtilisin/kexin type 9 (PCSK9) [3, 4]. World-
wide, more than 1200 mutations of LDLR gene have been
reported [5]. The clinical diagnosis of FH is based on various
diagnostic criteria such as Simon Broome, Dutch, and Great
Britain[6,7].Theidentiﬁcationandtreatmentofaﬀectedin-
dividuals is very important matter, since it has been doc-
umented that there is a signiﬁcant reduction of morbidity
and mortality with the lipid-lowering treatment [8]. Thus,
adequate control of plasma LDL cholesterol is crucial. In
majority of hFH patients, this can be achieved by diet and
drugs therapy combination. However, when the lipid-lower-
ing treatment is inadequate, the LDL apheresis is optional.
Therearestillsomeconsiderationsaboutdeﬁniteindications
for LDL apheresis in individuals with hypercholesterolemia.2 Cholesterol
Furthermore, there is a limited published experience about
the cardiovascular outcomes of patients treated with LDL
apheresis.
Until now, there are three categories of patients consid-
ered for LDL apheresis (see National Institute for Health and
Clinical Excellence (NICE), clinical guidelines) [9]:
(1) HFHwhosetotalcholesterol(TC)remained9mmol/l
(350mg/dL) or decreased <50% on drugs therapy,
(2) individuals with FH, progressive CAD and TC re-
mained 4.9mmol/l (190mg/dL) or decreased by 40%
on maximal drugs therapy,
(3) exceptionally, individuals with lipoprotein (a)
[Lp(a)] > 60mg/dL and progressive CAD whose LDL
cholesterol remained >3mmol/l (120mg/dL) despite
drug therapy.
Our aim was to present the impact of LDL apheresis in
children and adults with TC values resistant to current avai-
lable hypolipidemic medical treatment.
2. Patientsand Methods
2.1. Patients. Two pediatric patients aged 11 and 13 years old
with HFH and 19 adults (mean age 44 ± 11 years) with or
without FH were included in the study. Six patients (5 wom-
en) refused LDL apheresis treatment, one of whom died few
months later. The diagnosis for FH was based on Simon
Broome criteria involving DNA analysis (in majority of pa-
tients). Patients were treated with low-fat diet and maximum
dosesofoneofthestatins(3-hydroxy-3-methylglutarylcoen-
zymeAreductaseinhibitor)suchassimvastatin,atorvastatin,
rosuvastatin plus ezetimibe and/or colesevelam (since they
wereavailable),and/orfenoﬁbrate.Thefrequencyofthepro-
cedure (see below) was adjusted individually with an average
of 10–15 days. All patients were informed of the risks of the
apheretic procedures (allergic reactions, hypotension) before
giving written informed consent. This procedure has been
applied in Onassis Cardiac Surgery Center since 2004, and
the followup was carried out in an open, prospective uncon-
trolled clinical design.
The diagnosis of hFH was based on the following clinical
criteria:
(a) TC > 7.5mmol/l (290mg/dL), LDL cholesterol >
4.9mmol/l (190mg/dL),
(b) presence of tendon xanthomas in the patient or a 1st
or 2nd degree relative, are
(c) history of premature vascular disease in a 1st degree
relative <60 years or in 2nd degree relative <50 years
old.
In patients with HFH the direct adsorption of lipopro-
teins (DALI) procedure was oﬀered to those whose TC was
remained at 9mmol/l (350mg/dL) or decreased <50% on
drugstherapyandinpatientswithhFH,whohadprogressive
CAD and, their TC was remained at 4.9mmol/l (190mg/dL)
or decreased by <40% on maximal drugs therapy. In patients
without FH, the DALI procedure was oﬀered to those, who
had exhausted all other options of lowering their TC levels
and have an LDL level above 5mmol/l (200mg/dL) with
CAD or LDL cholesterol level of 7.7mmol/l (300mg/dL)
without the presence of CAD.
2.2. Methods. The main indication for use of the DALI sys-
tem was inability to reach target LDL cholesterol levels on
medical treatment that included diet and cholesterol-lower-
ing drugs.
DALI 500, 750, 1000 (500 + 500), and 1250 (500 + 750)
adsorbers were incorporated in the extracorporeal circuit.
Dali primer solution, acid citrate dextrose formula A (ACD-
A) solution, blood lines, and hemadsorption monitor 4008
ADS (Fresenius HemoCare Adsorber Technology GmbH,
St. Wendel, Germany) were used. Prior to the session, the
adsorberswererinsedwith3 ×2000mLofprimersolutionat
a ﬂow rate of 400mL/min. The ﬁrst 2L contained 20000IU
of heparin. The adsorbers were saturated with citrate during
priming.
Prior to the session the patients received an initial intra-
venous heparin bolus, followed by an ACD-A infusion dur-
ing the session. ADC-A was ﬁrst mixed with the patient’s
blood at a ratio of 1:20 and reduced to 1:40 after 1500mL
of blood were treated.
Twobilateralvascularaccessesbyvenipuncture,generally
in the median cubital veins, were established. At the start of
the session, the patient was only connected to the aﬀerent
(arterial) line of the extracorporeal circuit. All sessions were
carried out under blood pressure and electrocardiogram
monitoring, and DALI 750–1250 adsorbers were used for the
procedure.
2.3. Laboratory Measurements. At the start (before any pro-
cedure)andend(justbeforetakingtheneedle fromthe aﬀer-
ent arm) of each session, a blood sample was drawn for a
lipid proﬁle. Blood was collected in tubes containing EDTA.
Plasma TC, triglyceride (TG), and high-density lipoprotein
(HDL)cholesterollevelsweremeasuredusingenzymaticcol-
orimetric methods on a Roche Integra Biochemical analyzer
with commercially available kits (Roche). The serum LDL
cholesterol levels were calculated using the Friedewald
formula [10] only in patients with TG levels <4.5mmol/l
(400mg/dL). Calculated LDL cholesterol = TC − HDL cho-
lesterol − TG/5.0 (mg/dL). All samples were analyzed within
few hours.
The body mass index was calculated as weight divided by
height expressed in kg/m2.
2.4. Statistical Analysis. The results were expressed as mean
± standard deviation (SD). The Student’s t-test was used to
comparethecontinuousvariablesbetweengroups,atasigni-
ﬁcance level of P<0.05.
The acute diﬀerences in TGs, HDL cholesterol, and LDL
c h o l e s t e r o lb e f o r ea n da f t e rL D La p h e r e s i sw e r ed e s c r i b e da s
%d i ﬀerence, based on the following rule: % diﬀerence =
[(variablebefore −variableafter)/variablebefore]∗100.The
correction for haematocrit was made by measuring haemat-
ocrit at the start and at the ﬁnish of session and multiplyingCholesterol 3
theCmin value (cholesterol level immediately after an aphere-
sis) by the pre/postapheresis haematocrit ratio.
The interval mean was calculated using the equation
devised by Kroon el al. [11] Cmean = Cmin + K(Cmax − Cmin).
Cmin = cholesterol level immediately after an apheresis and
at the start of the subsequent procedure (Cmax). Kroon et al.
[11] proposed using a value of K = 0.73. Because calculation
of LDL cholesterol using the Friedewald equation has been
shown to underestimate the low concentrations seen imme-
diately after apheresis [12] and we have not performed direct
LDL cholesterol, the TC values only were used.
Survival analysis and Kaplan-Meier survival curve were
applied in order to evaluate the average annual cardiovascu-
lar event rate. Data were analyzed using STATA (Version 9.0,
Stata Corporation, College Station, TX, USA).
3. Results
The mean follow-up period was 47 ± 23 (range 9–81)
months. DALI 750 was performed in 10%, and DALI 1000 in
20% and DALI 1250 in 70%. Twenty-one patients (18 men)
underwent 2856 DALI sessions between June 2004 and
September 2011. The clinical characteristics of the patients
were presented in Table 1. The medication list shows the
current medication of participants. Patients who were in
angiotensin converting enzyme inhibitors prior entering the
DALI sessions were switched to calcium-channel blockers to
control the blood pressure. During the follow-up, in two pa-
tients, acenocoumarin was added due to aortic valve replace-
ment, and in two patients clopidogrel was added following
angioplasty. No other major changes in drug treatment were
done.
One patient has been previously treated with one session
of plasma exchange. Five patients were diagnosed with HFH
and 10 patients with hypercholesterolemia (familial or non-
familial). Six patients had mixed dyslipidemia with high TC
and extremely high TG levels and progression of CAD who
did not respond adequately to medical treatment. The aver-
ageTC,TG,HDL,andLDLcholesterollevelsbeforeandafter
t r e a t m e n to fa l la n di nH F Ha n dn o n - H F Ht r e a t e dp a t i e n t s
was shown in Tables 2 and 3.
The mean acute reduction of all DALI sessions was 75 ±
11% for LDL cholesterol, 50 ± 16% for TG, and 14 ± 7%
for HDL cholesterol. The interval mean for TC was 6.9 ±
1.9mmol/l (268 ± 75mg/dL).
Thirty-three percent of patients experienced cardiovas-
cular events; 2 cardiac deaths (71-year-old women and 54-
year-old men) independently of the sessions, 1 coronary by-
passgrafting,2aorticvalvereplacement,1percutaneouscor-
onary intervention angioplasty, and 1 carotid artery angio-
plasty (pathology report showed scarring of atheromatous
plaque and formation of a thick ﬁbrous cap). The average
annual event rate was 5.51%, Figure 1.
Themajoradverseeﬀects(mostlikelyattheﬁrstsessions)
wereallergicreactionsmanifestedasshortnessofbreathand/
or facial ﬂushing, nausea vomiting, serious hypotension, and
technical diﬃculties and were recorded in 10% of the pa-
tients. However, minor side eﬀects like puncture difﬁcul-
ties, technical problems, headache, dizziness, or hypotensive
Table 1: Baseline clinical characteristics of 21 patients with LDL
apheresis.
Age, years 41 ±14
Female 3 (14.3%)
BMI, kg/m2 27 ±4
Hypertension 11 (52%)
Diabetes 4 (19%)
Smoking 5 (24%)
Previous conditions
Myocardial infarction 6 (29%)
Coronary artery bypass grafting 10 (48%)
PCI angioplasty 5 (24%)
Medications
Beta-blockers 12 (57%)
ACE inhibitors 0 (0%)
Nitrates 2 (10%)
Calcium-channel blockers 6 (56%)
Statins 19 (90%)
Fibrates 7 (33%)
Colesevelam 14 (67%)
Ezetimibe 10 (48%)
Aspirin 10 (48%)
Clopidogrel 5 (24%)
Acenocoumarin 2 (10%)
LDL apheresis period, months 47 ±22
LDL cholesterol before entry 9.9±5.9mmol/l (384±229mg/dL)
LDLindicateslow-densitylipoprotein,PCIindicatespercutaneouscoronary
intervention, and ACE indicates angiotensin-converting enzyme. Values
wereexpressedasmeans ±standarddeviation(SD);othervalueswerenum-
bers of patients with percentages given in parentheses.
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Figure 1: Kaplan-Meier survival curve.
periods were present occasionally. All of them were rechal-
lenged, uneventfully.
4. Discussion
The DALI system is an exceptional whole-blood cholesterol
apheresis system. Since its introduction at the Onassis Car-
diac Surgery Center in 2004, 21 patients have been treated.4 Cholesterol
Table 2: Lipid proﬁle before and after LDL apheresis sessions in mg/dL.
TC TC HT corrected TG HDL cholesterol LDL cholesterol
Preapheresis 318 ±86 287 ±624 41 ±12 256 ±82
Postapheresis 122 ±62 133 ±68 183 ±488 35 ±10 65 ±41
%d i ﬀerence −61% ±13% −58% ±14% −50% ±16% −14% ±7% −75% ±11%
All data were expressed as mg/dL, mean ± SD. The mean data were based on multiple measurements (n = 1216, only sessions which had at least three
parameters,TC,TG,andHDLmeasuredwereinvolved)duringthetotalfollow-upperiod.AllvaluesweresigniﬁcantlydecreasedP<0.001aftertheprocedure.
To convert cholesterol values (TC, HDL, and LDL) from mg/dL to mmol/l, multiply by 0.0259, and, for TGs, multiply by 0.0113. TG indicates triglycerides,
LDL indicates low-density lipoprotein, and HDL indicates high-density lipoprotein (HT = hematocrit).
Table 3: Lipid proﬁle before and after LDL apheresis sessions in HFH and non-HFH patients.
TC TC HT corrected TG HDL cholesterol LDL cholesterol
HFH
Preapheresis 344 ±81 93 ±36 37 ±8 288 ±81
Postapheresis 111 ±44 121 ±47 42 ±23 32 ±77 2 ±45
%d i ﬀerence −68% ±8% −65% ±9% −55% ±14% −13% ±7% −76% ±10%
Non-HFH
Preapheresis 284 ±79 541 ±885 45 ±14 196 ±39
Postapheresis 137 ±78 149 ±85 367 ±700 39 ±12 53 ±30
%d i ﬀerence −53% ±14% −49% ±15% −42% ±16% −14% ±8% −72% ±14%
All data were expressed as mg/dL, mean ± SD. The mean data were based on multiple measurements (n = 1216, only sessions which had at least three
parameters, TC, TG, and HDL, measured were involved) during the total follow-up period. All values were signiﬁcantly decreased P<0.001, except HDL
cholesterol (P = 0.265) in non-HFH group. To convert cholesterol values (TC, HDL, and LDL) from mg/dL to mmol/l, multiply by 0.0259, and, for TGs,
multiply by 0.0113. TG indicates triglycerides, and LDL indicates low-density lipoprotein, HDL indicates high-density lipoprotein (HT = hematocrit).
Our results showed 61% acute reduction in TC and 75% in
LDL cholesterol beyond that achieved by previous medical
treatment. The interval mean for TC was 6.9 ± 1.9mmol/l
(268 ± 75mg/dL). A reduction of 50% in TGs was also ob-
s e r v e d .T h ea v e r a g ea n n u a le v e n tr a t ew a s5 . 5 1 % .
IntheLAARSstudy[13](angiographictrials),7outof21
patients had cardiac events, 3 unstable angina including one
cardiac death, and 4 myocardial infarction over 2 years; how-
ever, most of the events took place in the ﬁrst year. These
results were similar to our results. In L-CAPSb [14], 3 out of
25 patients had a cardiac event during a 2.3-year period, and
2patientsunderwentcoronaryinterventionwithin6months
of enrolment. In the Hokuriku study, where 43 hFH patients
withCADwereincluded[15],patientswhoweretreatedwith
LDL apheresis had LDL cholesterol reduced by 58%. More-
over, during a 6-year follow-up period, coronary events were
reduced by 72% (as compared to the group receiving drug
therapy alone).
In our group the percentage of event-free survival for 7
years was 67% that was moderately low and close to the con-
trol group of the Hokuriku study. Noteworthy to mention,
most of the patients, referred to us, were already presented
withclinical manifestations ofatherosclerosis[16–18].Inthe
study by Masaki et al. [19], the event-free survival with res-
pect to a major cardiac event (cardiac death and myocardial
infarction) was 94.4% for 6 years. The Liposorber Study
Group in the United States [20] examined the eﬀects of LDL
apheresis in a trial with a 5-year followup of 49 FH patients.
The rate of cardiovascular events (cardiac death, coronary
revascularization, myocardial infarction, or cerebrovascular
events) with LDL apheresis was 3.5 events per 1,000 patient-
months of treatment. Keller [21] reported the results of LDL
apheresis treatment in HFH, who were followed up for over
30 years. They found 21% deaths in group on LDL apheresis
compared with 43% in group without LDL apheresis. In
our study in LDL apheresis group, the 9.5% of deaths were
reported during a 7-year follow-up period, while, in patients
who were not treated with LDL apheresis, the 17% of deaths
were reported. Koziolek et al. [22] analysed retrospectively
approximately 10000 apheresis sessions performed in 38
patientsduringthepast20years(meanof9years)inGerman
and showed a decreasing incidence of major coronary events
with LDL apheresis.
There is still a small number of studies describing, the 10
year and over, the clinical impact of LDL apheresis and coro-
nary artery disease outcomes. Although these patients are
usually at extreme risk to develop major clinical events, sev-
eral doctors still have some reservation towards referring
drug-resistance patients for LDL apheresis. Furthermore,
many doctors are not familiar with the regulations concern-
ingtheindicationreimbursementforLDLapheresisreported
by Societies for Apheresis [23–25].
However, the end results are in favor for LDL apheresis
that is a promising tool for retarding or arresting the athero-
sclerosis process in refractory hypercholesterolemic patients.
Koga and Iwata [26] in a pathology report showed scarring
of atheromatous plaque and formation of a thick ﬁbrous cap
after 7 years of LDL apheresis in a FH patient, similar to our
ﬁnding.
Limitations of the study are the following. The LDL
apheresisisaninvasiveprocedure,performedonlyinselected
hospitals on an out- or in-patient basis. During this proce-
dure (which takes approximately 2 hours), an experienced
physician and/or technician (nurse) has to be present. More-
over, the procedure still remains expensive.Cholesterol 5
In conclusion, LDL apheresis is a very important tool in
managing patients at high risk of premature CAD, such as
those with FH or with progressive, aggressive CAD despite
adequate medical treatment. Therefore, the early considera-
tion of LDL apheresis as a lifesaving procedure for these pa-
tients is of great value.
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